Aptargroup, Inc. · NYSE:ATR
Aptargroup — Q2 2024 Earnings Presentation
23 slides from Aptargroup's earnings presentation, Jul 26, 2024
Slide 1: Q2 2024 Results
Q2 2024 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO July 26, 2024
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q2 2024 Financial Highlights
Q2 2024 Financial Highlights Highlights: +2% Reported Sales Growth +3% Core Sales Growth* • Solid second quarter results driven by continued growth of the company’s proprietary drug delivery systems and margin improvement • Grew adjusted EPS double digits for the first half of the year, and in the q
Slide 4: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Beauty Aptar Closures • Aptar’s unidose system is used on a medication in • Lancôme partnered with us on a fragrance • Kraft Heinz’s rebranded Mio packaging in the US the US to treat vitamin B12 deficiency and anemia pump for the refi
Slide 5: Sustainability Highlights
Sustainability Highlights Aptar’s 2023 Corporate Sustainability / ESG Report • Report summarizes milestones measured and achieved in the key areas of our global sustainability strategy • Alignment to GRI with supplemental SASB report • Third-party "reasonable assurance" on Scope 1 and 2; third-party
Slide 6: Second Quarter 2024 Reported Results
Second Quarter 2024 Reported Results Q2 Reported Sales Q2 Reported EPS Q2 Highlights (in millions $) $1,200 $1.60 8% $1.34 • Aptar Pharma’s strong performance was driven by $1.40 $1,000 $896 2% $910 $1.24 continued growth for proprietary drug delivery $1.20 $800 systems used for allergic rhinitis, c
Slide 7: Second Quarter 2024 Adj. EPS and Adj. EBITDA
Second Quarter 2024 Adj. EPS and Adj. EBITDA Q2 Adjusted EPS Q2 Adjusted EBITDA $1.60 $250 (in millions $) * $1.37 $1.40 12% $1.22 $200 6% $193 $1.20 $181 $1.00 $150 $0.80 $0.60 $100 $0.40 $50 $0.20 $- Q2 2023 Q2 2024 $- Q2 2023 Q2 2024 25% 24% Adjustments: • 2023: Restructuring Initiatives of $1.9
Slide 8: Year-to-Date 2024 Reported Results
Year-to-Date 2024 Reported Results YTD Reported Sales (in millions $) YTD Reported EPS Year-to-Date Highlights $2,500 $3.00 $2.57 $2,000 $1,756 4% $1,826 $2.50 24% • Strong first half of the year $2.07 $2.00 $1,500 $1.50 • Double-digit EPS growth over the prior $1,000 $1.00 year period $500 $0.50 •
Slide 9: Year-to-Date 2024 Adj. EPS and Adj. EBITDA
Year-to-Date 2024 Adj. EPS and Adj. EBITDA YTD Adjusted EPS YTD Adjusted EBITDA * $3.00 (in millions $) $450 $2.63 $400 11% $372 $2.50 21% $335 $2.18 $350 $2.00 $300 $250 $1.50 $200 $150 $1.00 $100 $50 $0.50 $- YTD 2023 YTD 2024 $- YTD 2023 YTD 2024 Adjustments: 25% 22% • 2023: Restructuring Initiat
Slide 10: Outlook
Outlook Outlook Highlights • Strong first half, and we expect growth to continue in the Earnings Per Share third quarter $1.60 • Anticipate growth for our proprietary drug delivery $1.40 $1.37 $1.38 – $1.46 23.5-25.5% systems to continue, driven by increased demand for $1.26 nasally delivered centra
Slide 11: Appendix
Aptar.4 Appendix
Slide 12: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 12
Slide 13: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 13
Slide 14: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share Effective Tax Rate (Unaudited) Adjusted Earnings* = Adjusted Provision for Income Taxes / ($ In Thousands Adjusted Earnings Except Per Share before Income Taxes Data) 14
Slide 15: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 15
Slide 16: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 17
Slide 18: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 18
Slide 19: Stockholders' Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 19
Slide 20: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 20
Slide 21: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 21
Slide 22: Supplemental Information
Supplemental Information 22
Slide 23: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 23